Skip to main content
Monday, November 16, 2026Nov 16

US stocks jump as energy companies and Apple move higher

In this Friday, Oct. 7, 2016, photo, a statue of George Washington is poised above Wall Street, in New York. U.S. stocks are rising early Monday, Oct. 10, 2016, as energy companies climb with the price of oil. Apple is leading technology stocks higher as Samsung’s Galaxy Note 7 is beset by new problems. Drugmaker Mylan is up after it agreed to settle an investigation into allegations it overcharged the government for its EpiPen shot. (AP Photo/Mark Lennihan)
In this Friday, Oct. 7, 2016, photo, a statue of George Washington is poised above Wall Street, in New York. U.S. stocks are rising early Monday, Oct. 10, 2016, as energy companies climb with the price of oil. Apple is leading technology stocks higher as Samsung’s Galaxy Note 7 is beset by new problems. Drugmaker Mylan is up after it agreed to settle an investigation into allegations it overcharged the government for its EpiPen shot. (AP Photo/Mark Lennihan)

NEW YORK (AP) – U.S. stocks are climbing in Monday morning trading as energy companies rise in tandem with the price of oil. Materials companies are also trading higher. Apple is rising after new reports of fires affecting Samsung’s Galaxy Note 7 phone, which competes with Apple’s iPhone. That’s sending technology stocks higher.

KEEPING SCORE: The Dow Jones industrial average jumped 142 points, or 0.8 percent, to 18,382 as of 10:05 a.m. Eastern time. The Standard & Poor’s 500 index rose 15 points, or 0.7 percent, to $2,168. The Nasdaq composite added 47 points, or 0.9 percent, to 5,339.

ENERGY: Benchmark U.S. crude rose $1.24, or 2.5 percent, to $51.05 a barrel in New York while Brent crude, used to price international oils, gained $1.27, or 2.4 percent, to $53.20 a barrel in London. Exxon Mobil climbed $1.69, or 1.9 percent, to $88.43 and Murphy Oil added 89 cents, or 3 percent, to $30.40.

SHOT IN THE ARM: Drugmaker Mylan gained $3.51, or 9.8 percent, to $39.45. On Friday the company agreed to pay $465 million to settle allegations it overcharged the Medicaid program for its EpiPen shot. Legislators and federal health authorities had said Mylan wrongly classified EpiPen as a generic drug instead of a brand-name one, which meant Mylan paid lower rebates to federal and state Medicaid programs. The stock is down 19 percent since late August.

BRISTOL BUMPED: Bristol-Myers Squibb lost $5.08, or 9.2 percent, to $50.35 after the company reported new data from a study of its drug Opdivo in lung cancer patients. Stronger results could have expanded use and sales of Opdivo. The stock has dropped 33 percent since the company announced initial results from that trial in early August. Rival Merck rose 92 cents, or 1.5 percent, to $63.69.